title: Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer.
authors.affiliation: Urology Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Clinical Sciences Unit, Leicester General Hospital, Leicester, United Kingdom.
authors.forename: Lynsey A
authors.initials: LA
authors.lastname: McHugh
authors.forename: T R Leyshon
authors.initials: TR
authors.lastname: Griffiths
authors.forename: Marina
authors.initials: M
authors.lastname: Kriajevska
authors.forename: R Paul
authors.initials: RP
authors.lastname: Symonds
authors.forename: J Kilian
authors.initials: JK
authors.lastname: Mellon
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D018773:Genes, erbB-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D019042:Muscle Neoplasms / Q000188:drug therapy / Q000556:secondary; D020360:Neoadjuvant Therapy; D018739:Oncogene Proteins v-erbB / Q000037:antagonists & inhibitors; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D051057:Proto-Oncogene Proteins c-akt; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000187:drug effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D004317:Doxorubicin; D004791:Enzyme Inhibitors; D066246:ErbB Receptors; D000077156:Gefitinib; D008727:Methotrexate; D018739:Oncogene Proteins v-erbB; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D011799:Quinazolines; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D014747:Vinblastine